CDMO Market Size 2026: The Data Behind a Growing Outsourcing Opportunity

The contract development and manufacturing organization (CDMO) sector is one of the most resilient growth stories in life sciences, and 2026 is shaping up to be a pivotal year. Pharma and biotech sponsors continue to externalize more of their development and manufacturing, specialist modalities keep multiplying, and demand for GLP-1 and biologics capacity is reshaping where the money flows. For CDMOs trying to win new programs, knowing the numbers is not academic: it tells you which segments are expanding fastest, where competition is thickest, and how to position a business development conversation.

This article pulls together current, sourced figures on the market, breaks down the biologics versus small molecule story, and translates the data into practical implications for commercial teams.

Key Takeaways

• Market scale: The global CDMO market is worth roughly USD 270 to 275 billion in 2026, depending on the research firm, with most forecasts pointing to USD 375 to 580 billion by the early 2030s.

• Growth rate: Consensus growth sits in the 6 to 10 percent CAGR range, comfortably above broader pharma manufacturing, driven by rising outsourcing penetration.

• Biologics outpace small molecule: Biologics CDMO services are growing faster (roughly 7 to 15 percent CAGR depending on scope) than small molecule, though small molecule and APIs still hold the larger absolute share.

• North America leads: North America remains the largest regional market, holding around 40 to 43 percent of small molecule CDMO revenue, with the US alone projected near USD 42 billion in 2026.

• BD implication: Capacity in sterile fill/finish and specialized modalities is tight, so CDMOs that can credibly promise speed and capacity have real pricing and positioning leverage.

How big is the CDMO market in 2026?

Let's start with the headline number. The cdmo market size 2026 estimates vary by firm because each uses a different scope and methodology, but the cluster is tight enough to be useful. Mordor Intelligence puts the global pharmaceutical CDMO market at about USD 275.27 billion in 2026, growing to roughly USD 374.68 billion by 2031 at a 6.33 percent CAGR. Fortune Business Insights lands near USD 273.40 billion in 2026 but projects faster growth, around 9.90 percent CAGR, reaching about USD 580.72 billion by 2034.

More conservative scopes, such as Precedence Research, estimate about USD 211 billion in 2026 expanding to roughly USD 392.67 billion by 2035 at a 7.12 percent CAGR. The differences mostly come down to whether a firm counts only outsourced manufacturing or includes the full development-plus-manufacturing value chain.

The practical takeaway: treat any single figure as approximate. What matters is the direction and the pace. Every credible source agrees the market is growing meaningfully faster than the underlying pharmaceutical industry, because the share of work that sponsors outsource keeps rising.

CDMO market size 2026: a side-by-side comparison

The table below puts the leading 2026 estimates next to one another so you can see the range at a glance.

Source	2026 market size (approx.)	Forecast	CAGR
Mordor Intelligence	USD 275.27 billion	USD 374.68 billion by 2031	~6.33%
Fortune Business Insights	USD 273.40 billion	USD 580.72 billion by 2034	~9.90%
Precedence Research	USD 211 billion	USD 392.67 billion by 2035	~7.12%
US market (Towards Healthcare)	USD 41.65 billion	USD 72.98 billion by 2035	~6.43%

Reading across the row, the spread on the 2026 figure (roughly USD 211 to 275 billion) is the scope effect described above. The spread on growth (6 to 10 percent) reflects different assumptions about how quickly biologics, GLP-1, and advanced modalities scale. For a business development plan, anchoring to the midpoint and qualifying it as "about" is the honest and defensible approach.

Biologics versus small molecule: where is growth concentrated?

The single most important segmentation question for a CDMO's commercial strategy is biologics versus small molecule, because the two have very different growth profiles, margins, and capital requirements.

Biologics CDMO

Biologics is the faster-growing engine. Precedence Research calculates the biologics CDMO market at about USD 23.08 billion in 2025, rising to roughly USD 25.08 billion in 2026. MarketsandMarkets-style estimates put the 2026 figure near USD 27.13 billion, growing at about 7.14 percent CAGR to USD 38.29 billion by 2031. More aggressive scopes report CAGRs as high as 15.7 percent. The wide range again reflects scope, but the relative message is consistent: biologics is gaining share inside the CDMO mix.

Small molecule CDMO

Small molecule is the larger base and remains very much alive, contrary to the "biologics will eat everything" narrative. The small molecule innovator CDMO market is projected to climb from about USD 60.7 billion in 2025 to roughly USD 65.83 billion in 2026 at an 8.4 percent CAGR. The active pharmaceutical ingredient (API) CDMO segment is even bigger, projected at about USD 125.99 billion in 2026 on its way to roughly USD 247.60 billion by 2035 at a 7.81 percent CAGR, with the API segment holding around 38.5 percent of the overall market in 2025. High-potency APIs and peptide-based GLP-1 therapies are pulling small molecule growth upward, which is why writing off the segment would be a strategic mistake.

The honest summary: biologics grows faster in percentage terms, but small molecule plus API is the larger absolute market and is being revitalized by GLP-1 peptides and HPAPIs. A CDMO's positioning should reflect which of these it actually serves, not which sounds more exciting.

Regional picture: North America leads, Europe and Asia-Pacific scale

Geography still matters enormously for business development, because proximity, regulatory familiarity, and supply chain security all influence sponsor decisions. North America held the dominant position in small molecule CDMO, accounting for about 42.7 percent share and roughly USD 29.1 billion in 2024, and around 40 percent of the global small molecule CMO and CDMO market. The US pharmaceutical CDMO market alone is forecast to rise from about USD 41.65 billion in 2026 to roughly USD 72.98 billion by 2035 at a 6.43 percent CAGR.

Asia-Pacific is the fastest-growing region in percentage terms, with specific country markets exhibiting CAGRs near 9.4 percent, partly on cost and partly on expanding domestic biotech. Europe sits between the two: a mature, quality-driven market where supply chain resilience and "friendly-shoring" of critical APIs are increasingly part of the sponsor conversation. For CDMOs targeting US and EU sponsors, the resilience-and-reshoring theme is now a credible differentiator, not just a talking point.

What is driving CDMO growth into 2026?

Several forces are compounding. First, GLP-1 demand: total GLP-1 sales are projected to exceed USD 200 billion annually by 2031, and the buildout to meet that demand accelerates in earnest in 2026, with sponsors like Eli Lilly investing in multi-billion-dollar facilities. Second, capacity constraints: sterile fill/finish capacity remains tight and specialized modalities have a backlog, which is expected to persist through 2026. Third, an easing biotech funding environment is unlocking programs that were paused during the funding winter, especially those with strong data.

For business development, tight capacity is a double-edged sword. It gives CDMOs pricing leverage, but it also means sponsors are doing more diligence on whether a partner can actually deliver on time. The winning BD narrative in 2026 leads with demonstrable capacity and speed, backed by evidence, rather than a generic capabilities list.

Turning market data into a business development advantage

Numbers only matter if they change what you do on Monday morning. A CDMO that understands the cdmo market size 2026 landscape can prioritize the segments where demand outpaces supply (sterile fill/finish, peptides, biologics), tailor outreach to the regions where its quality and proximity story resonates, and qualify leads against the modalities it genuinely excels at. This is exactly the kind of market-informed targeting that separates a predictable pipeline from spray-and-pray outreach.

If you want to translate these trends into a structured pipeline, our guide to pipeline optimization walks through building a predictable revenue engine, and our breakdown of business development challenges for CDMOs addresses the specific commercial hurdles this sector faces. For the upstream demand-generation side, pharmaceutical lead generation covers how to fill the top of the funnel, and if you are weighing channel strategy, inbound vs outbound in life sciences explains why you need both.

Frequently asked questions

How big is the CDMO market in 2026?

The global CDMO market is worth roughly USD 211 to 275 billion in 2026, depending on the research firm and the scope of services counted. Most estimates cluster around USD 270 billion, with forecasts reaching USD 375 to 580 billion by the early-to-mid 2030s.

What is the CDMO market growth rate?

Consensus growth sits in the 6 to 10 percent CAGR range. Mordor Intelligence cites about 6.33 percent to 2031, while Fortune Business Insights projects closer to 9.90 percent to 2034. Biologics and GLP-1-related capacity grow faster than the overall average.

Is biologics or small molecule growing faster in the CDMO market?

Biologics is growing faster in percentage terms, with CAGRs reported between roughly 7 and 15 percent depending on scope. However, small molecule plus API services remain the larger absolute market and are being revitalized by GLP-1 peptides and high-potency APIs.

Which region has the largest CDMO market?

North America is the largest, holding around 40 to 43 percent of small molecule CDMO revenue, with the US market alone forecast near USD 42 billion in 2026. Asia-Pacific is the fastest-growing region, and Europe is a mature, quality-driven market increasingly shaped by supply chain resilience.

Why is the CDMO market growing so quickly?

Three drivers dominate: surging GLP-1 demand (projected above USD 200 billion in annual sales by 2031), persistent capacity constraints in sterile fill/finish and advanced modalities, and an easing biotech funding environment that is unlocking previously paused programs.

Sources

• Mordor Intelligence, Pharmaceutical CDMO Market: https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-market

• Fortune Business Insights, CDMO Outsourcing Market: https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502

• Precedence Research, Pharmaceutical CDMO Market: https://www.precedenceresearch.com/pharmaceutical-cdmo-market

• Precedence Research, Biologics CDMO Market: https://www.precedenceresearch.com/biologics-cdmo-market

• Grand View Research, Small Molecule Innovator CDMO Market: https://www.grandviewresearch.com/industry-analysis/small-molecule-innovator-cdmo-market-report

• BioSpace, API CDMO Market: https://www.biospace.com/press-releases/active-pharmaceutical-ingredients-api-cdmo-market-size-usd-247-60-bn-by-2035-rising-demand-for-hpapis-and-biologics-drives-growth

• Towards Healthcare, US Pharmaceutical CDMO Market: https://www.towardshealthcare.com/insights/us-pharmaceutical-cdmo-market-sizing

• Outsourced Pharma, 2025 GLP-1 Impacts on CDMOs in 2026: https://www.outsourcedpharma.com/doc/2025-glp-impacts-tell-us-about-cdmos-in-0001

Author: Imen Jelassi, Founder, Corstrate, Life Sciences Business Development Consultant.